Webinar: Pediatric Sickle Cell Disease: A Pharmacological Update – Past, Present, and Future

$25.00

This webinar will provide a foundational overview of SCD’s pathophysiology, inheritance, and impact on health, including the role of newborn screening in early detection. The session will then focus on newer pharmacologic treatments—such as Crizanlizumab, Endari, and the recently withdrawn Voxelotor—highlighting their mechanisms, indications, side effects, and the importance of post-marketing safety monitoring. Nursing considerations, including administration, adverse effect management, and patient education, will be emphasized, along with a brief look at future directions like gene therapy.

Want a discount? Become a member!

Specs

Category:

Description

Pediatric Sickle Cell Disease: A Pharmacological Update – Past, Present, and Future

Presented by:

  • Dr. Patricia A. Clarke, DNP, APRN, CPNP-PC, CPHON 
  • Quynh T. Remmel, PharmD
  • Brian Bui, PharmD, BCPS

Livestream Webinar via Zoom

Date: June 25, 2025

Time: 2:00 PM EST (11:00 AM PST, 12:00 PM MST, 1:00 PM CST)

Presented by: Dr. Patricia A. Clarke, DNP, APRN, CPNP-PC, CPHON

Overview of the Session

This webinar will provide an update on Pediatric Sickle Cell Disease (SCD), focusing on its pathophysiology, epidemiology, and new pharmacological treatments. It aims to enhance understanding of SCD’s impact and the nursing considerations in managing the disease.

The session will explore: 

  • Overview of Sickle Cell Disease: SCD is a prevalent inherited hemoglobinopathy in the U.S., affecting approximately 100,000 individuals, particularly among African Americans and Hispanic Americans. The webinar will discuss its genetic basis, complications, and the significance of newborn screening.
  • New Pharmacologic Treatments: The session will cover recent advancements in treatments for SCD, including Crizanlizumab and Endari, as well as the implications of Voxelotor’s withdrawal due to safety concerns.
  • Nursing Considerations: Important nursing strategies will be addressed, such as medication administration, managing adverse reactions, and patient education, ensuring effective care for SCD patients.
  • Future Directions: The webinar will conclude with a discussion on emerging therapeutic approaches, including gene therapy, highlighting potential advancements in SCD treatment.

*NOTE: Live Webinar  link and evaluation are located in “My Courses- ACE Center” after registration is complete

Upon successful completion of this course, nurses will earn 1 NCPD. There are pharmacology hours associated with this activity.

Association for Pediatric Hematology Oncology Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. Provider approved by the California Board of Registered Nursing, Provider Number 14513.

Individual Learning Needs Assessment (ILNA) Coding
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. You may claim 1 NCPD in one of the following ILNA categories: Care Continuum, Psychosocial Dimensions of Care, OR Care of the Pediatric Hem/Onc Patient 
Please reach out to the Education Team at education@aphon.org with your name, the email associated with your APHON account, and the above ILNA category you would like to have reflected on your certificate and APHON can update your completion certificate to reflect your choice.

Any questions? Contact education@aphon.org

Related products